ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Ranbaxy secures FDA approval for quinapril hydrochloride + hydrochlorothiazide tablets

Ranbaxy Pharmaceuticals has announced approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg.

5 Mar 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that "the use of evidence-based treatments appears to be imbalanced according to the gender of the patient".

23 Jan 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

21 Jan 2009

Sildenafil may help protect heart from high blood pressure damage

Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein.

5 Jan 2009

ACE inhibitor calcium channel blocker combo drug shown to reduces heart attacks

While doctors are urged to start with a diuretic-based strategy to control patients' high blood pressure, an international blood pressure study shows a different single-pill drug combination is more effective at preventing heart-related events such as heart attacks and strokes.

3 Dec 2008

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

3 Dec 2008

Financial incentives motivates doctors to reduce ethnic differences in heart disease treatments

Financial incentives for doctors can improve the management of coronary heart disease (CHD) and reduce ethnic differences in quality of and access to care, according to Dr. Christopher Millett, Consultant in Public Health at Imperial College Faculty of Medicine in London in the UK, and his colleagues.

17 Nov 2008

Regularly exercise good for heart failure patients

Heart failure patients who regularly exercise fare better and feel better about their lives than do similar patients who do not work out on a regular basis, say researchers at Duke University Medical Center.

12 Nov 2008

Without enzyme, biological reaction essential to life takes 2.3 billion years

All biological reactions within human cells depend on enzymes. Their power as catalysts enables biological reactions to occur usually in milliseconds. But how slowly would these reactions proceed spontaneously, in the absence of enzymes - minutes, hours, days? And why even pose the question?

12 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Experts available to comment on risk of sudden cardiac death in 30 days following a heart attack

A new study in the November 5th 2008 issue of JAMA finds that during the first month after a heart attack, patients may have an increased risk for sudden cardiac death.

5 Nov 2008

Cheap 'Polypill' deals with heart disease and stroke

The 'Polypill' is a single pill which combines a range of drugs that protect against heart disease and stroke and was first considered a number of years ago as a cost effective way to significantly reduce the death toll from cardiovascular disease. But progress has been hampered by the reluctance of pharmaceutical companies to embark on a project involving inexpensive drugs which offered little financial incentive.

7 Oct 2008

Depressed dialysis patients more likely to be hospitalized or die, researcher finds

Dialysis patients diagnosed with depression are nearly twice as likely to be hospitalized or die within a year than those who are not depressed, a UT Southwestern Medical Center researcher has found.

14 Sep 2008

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.

31 Aug 2008

Researchers devise means to create blood by discovering earliest form of human blood stem cells

Johns Hopkins researchers have discovered the earliest form of human blood stem cells and deciphered the mechanism by which these embryonic stem cells replicate and grow. They also found a surprising biological marker that pinpoints these stem cells, which serve as the progenitors for red blood cells and lymphocytes.

28 Aug 2008

Garlic supplements may help control high blood pressure

According to a new review of relevant research, garlic supplements may be as effective at lowering blood pressure as some hypertension drugs.

4 Aug 2008

Pregnancy increases risk of acute myocardial infarction

Although acute myocardial infarction (AMI) is rare in women of child-bearing age, pregnancy can increase a woman's risk of heart attack 3- to 4-fold, according to a study published in the July 15, 2008, issue of the Journal of the American College of Cardiology.

8 Jul 2008

Losartan shows promise in treating Marfan syndrome

A small study in 18 pattients assessing the effectiveness of the drug losartan for treating Marfan syndrome in children has yielded encouraging results.

25 Jun 2008

EUROACTION Trial: A comprehensive approach to cardiovascular prevention

The single largest research project ever to be undertaken by the European Society of Cardiology (ESC), EUROACTION, showed that a multidisciplinary, family based and nurse coordinated programme made a real difference in improving lifestyle and reducing cardiovascular risk among coronary patients and people with a high risk of developing Cardiovascular Disease (CVD).

15 Jun 2008

Thiazide-type diuretic shown to be best first-choice drug for hypertensive patients

A study based at The University of Texas Health Science Center at Houston provides added justification that a thiazide-type diuretic is the best first-choice drug for hypertensive patients. The findings, published in the American Heart Association's Circulation, Volume 117, Issue 20, evaluate the results of a previous trial coordinated by researchers at The University of Texas School of Public Health, along with other recent studies.

19 May 2008

ACE Inhibitors News and Research

Further Reading

Ranbaxy secures FDA approval for quinapril hydrochloride + hydrochlorothiazide tablets

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

Sildenafil may help protect heart from high blood pressure damage

ACE inhibitor calcium channel blocker combo drug shown to reduces heart attacks

Generics as good as brand-name drugs when treating heart diseases

Financial incentives motivates doctors to reduce ethnic differences in heart disease treatments

Regularly exercise good for heart failure patients

Without enzyme, biological reaction essential to life takes 2.3 billion years

FDA approves Ranexa for the treatment of chronic angina

Experts available to comment on risk of sudden cardiac death in 30 days following a heart attack

Cheap 'Polypill' deals with heart disease and stroke

Depressed dialysis patients more likely to be hospitalized or die, researcher finds

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

Researchers devise means to create blood by discovering earliest form of human blood stem cells

Garlic supplements may help control high blood pressure

Pregnancy increases risk of acute myocardial infarction

Losartan shows promise in treating Marfan syndrome

EUROACTION Trial: A comprehensive approach to cardiovascular prevention

Thiazide-type diuretic shown to be best first-choice drug for hypertensive patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News